CClinicalTrials.gg
CompletedNCT03319173Updated Nov 12, 2019Results posted

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

An interventional study of Dietary intervention in Mild Cognitive Impairment and Metabolic Syndrome, sponsored by Bristlecone Health, Inc.. Completed at 1 site in United States. Open to participants aged 35 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Bristlecone Health, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Study summary

The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts in global DNA (deoxyribonucleic acid) methylation (away from nutrient availability and toward biosynthesis) are initiated by chronic metabolic inflexibility, over-activation of the mTOR (mammalian target of rapamycin) pathway, and the deregulation of neural oxidative phosphorylation.

Read the detailed description

Nutritional epigenetics denotes gene-diet interactions and highlights the modulatory role of cellular energy status in aging and age-related diseases like cancer, cardiovascular disease (CVD), diabetes and neurodegeneration. Nutrients are epigenetic modifiers; macro and micronutrients regulate the placement and distribution of DNA histone modifiers distinguishing phenotype from genotype. Cellular energy status (AMP/ATP) modulates the regulatory mechanics of DNA methylation via the SAM (S-adenosylmethionine) methlytransferase and the SAH (S-adenosyl homocysteine) methyltransferase inhibitor index. Whole blood histamine and homocysteine levels provide additional information on the status of methylation. Hyperinsulinemia and cellular insulin resistance dysregulate nutrient sensing pathways; perpetual fed-state signaling exacerbates systemic metabolic inflexibility. Chronic elevations in insulin with long-standing impairments in glucose delivery are associated with profound changes in epigenetic expression consequent of hyper-activation of mTOR and inhibition of AMPK kinase pathways. Dietary ketosis is known to govern adaptive mitonuclear energy availability by increasing cellular reduction potential via >AMP/ATP ratio. AMPK activation adapts rRNA synthesis away from fed-state growth/storage toward energy production/release, common to fasted-states. Research suggests that induced and controlled dietary ketogenesis, a fasting mimetic, transcriptionally modifies gene expression thereby attenuating metabolic diseases.

The study will explore whether early stage memory loss (SMC \& MCI) and comorbidity of Metabolic Syndrome are symptomatic of peripheral and cerebral hypo-metabolism resultant of sustained cellular insulin resistance. The investigators will attempt to show that consequent to systemic hyperinsulinemia, mitonuclear crosstalk dysregulates the energy sensing kinases, mTOR/AMPK, thereby modifying the intra/extracellular nutrient signaling pathways. The suppression of AMPK, coupled with chronic fed-state signaling, adapts rRNA synthesis away from nutrient availability toward ATP consuming processes. Increased biosynthesis of proteins, lipids and cholesterol with concurrent inhibition of fat oxidation, energy cofactors (NAD+, SAHH) and programmed apoptosis results in the epigenetic drift of methylation toward global gene activation with region-specific silencing of key regulatory/longevity genes, SIRTs (sirtuins), FOX03 and Nrf2. This global shift in energy is marked by suppression of the SAM/SAH methylation index and correlative jumps in whole blood histamine and/or homocysteine. The study explores whether the aforementioned shift in nutrient sensing pathways modulates metabolic inflexibility via energy shunts toward cytosolic, substrate level phosphorylation via activation of PDK (pyruvate dehydrogenase kinase). An insulin resistant energy surplus (\<AMP/ATP) fosters low cellular reduction potential, which triggers mitonuclear crosstalk inhibiting oxidative ATP via PDC (pyruvate dehydrogenase complex), the regulatory gateway between anaerobic glycolysis and oxidative mitochondrial respiration. The study will attempt to show that induced and controlled dietary ketosis initiates the spontaneous/favorable release of energy ( >AMP/ATP), activating the AMPK circuitry thereby inhibiting the synthesis/storage of protein, cholesterol and lipids. Thus, a shift in cellular energy from low reduction potential (ATP/NADH) to high reduction potential (AMP/NAD+) attenuates methylation drift evidenced by marked reductions in biosynthesis: fasting lipid profile (TRI., VLDL, LDL, HDL), LP-IR score (particle concentration/size), HgA1c, fasting insulin, HOMA-IR and epigenetic modification of DNA measured by improved methylation index (>SAM/SAH) with correlating reductions in whole blood histamine and/or homocysteine. The resultant change in cerebral glucose metabolism and correlative improvement in SMC/MCI will be assessed by valid clinical measures of cognition: Montreal Cognitive Assessment (MoCA), Brief Visual Memory Test-Revised (BVMT-R) and Rey Auditory Verbal Learning Task (RAVLT) administered at baseline and weeks 2/4/6/8/10/12.

Research Question: Are selective memory complaints (SMC), mild cognitive impairments (MCI) and comorbid Metabolic Syndrome symptomatic of peripheral/cerebral insulin resistance with a resultant epigenetic drift in methylation away from energy production toward anabolic synthesis/storage, initiated and sustained by metabolic inflexibility, aerobic glycolysis and PDK inhibition of oxidative phosphorylation?

02

Conditions studied

  • Mild Cognitive Impairment
  • Metabolic Syndrome

Keywords

  • Mild Cognitive Impairment
  • AMPK activation
  • DNA global hypo-methylation
  • Metabolic Syndrome
  • Ketogenic diet
  • SAM/SAH Index
  • S-adenosylmethionine (SAM)
  • S-adenosylhomocysteine (SAH)
  • Region-Specific hyper-methylation
  • mTOR kinase pathway
  • AMP/ATP ratio
  • Low Reduction Potential
  • High Reduction Potential
  • Delta G
  • Exergonic
  • Endergonic
  • Epigenetic Histone Modification
  • Montreal Cognitive Assessment (MoCA)
  • Brief Visual Memory Test-Revised (BVMT-R)
  • Rey Auditory Verbal Learning Task (RAVLT)
  • HOMA-IR
03

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or Female (age 35-80)
  • Previously diagnosed with MetS and/or T2DM as measured by possessing at least two of the following physiological measures: type 2 diabetes, BMI > 30, HgA1c > 5.7%, waist/height ratio > .6, fasting glucose > 125 mg/dL
  • Subjective Memory Complaints (SCM) - Subjects score > 3 'yes' answers on the Subjective Memory Complaints Questionnaire
  • Previously diagnosed with Mild Cognitive Impairment (MCI)

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed with Alzheimer's disease (AD), dementia or Parkinson's disease
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Experimental group

    Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate. Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week.

    Behavioral: Dietary intervention

  • Active comparator
    Control group

    Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat. Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week.

    Behavioral: Dietary intervention

Interventions

  • BehavioralDietary intervention

    Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).

05

What researchers measure

Primary outcomes

  1. MoCA (Montreal Cognitive Assessment)

    Measures changes in cognitive function over time. Score: 30 points (maximum), 0 points (minimum). Score \>25 = normal cognitive function. Score 17-25 = mild cognitive impairment (MCI). Score \<17 = increased likelihood of Alzheimer's Disease or dementia.

    Time frame: 12 weeks

Secondary outcomes

  1. NMR Lipoprofile Particle Size - Small LDL-P

    Assessment of changes in Small LDL-P (total small Pattern B)

    Time frame: 12 weeks

  2. NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45

    Lipoprotein insulin resistance (LP-IR) is an aggregate score of the 6 lipoprotein parameters range from 0 to 100, with higher scores indicating greater insulin resistance (IR).

    Time frame: 12 weeks

  3. Fasting Triglycerides

    Assessment of changes in fasting triglycerides over time. Ranges: \< 150 mg/dL

    Time frame: 12 weeks

  4. Triglyceride/HDL Ratio

    Assessment of changes in Triglyceride/HDL ratio over time.

    Time frame: 12 weeks

  5. Fasting Insulin

    Assessment of changes in fasting insulin over time. Ranges: \< 2.6-11.1 mU/L

    Time frame: 12-weeks

  6. Fasting Glucose

    Assessment of changes in fasting glucose over time. Ranges: \< 74-100 mg/dL

    Time frame: 12-weeks

  7. HOMA-IR

    Assessment of changes in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) over time. Ranges: \< 1.0

    Time frame: 12-weeks

  8. HgA1c

    Assessment of changes in HgA1c (Hemoglobin A1c) over time.

    Time frame: 12-weeks

  9. Weight

    Assessment of changes in weight over time as measured in pounds.

    Time frame: 12-weeks

  10. Body Fat Mass (BFM)

    Assessment of changes in body fat mass over time as measured in pounds.

    Time frame: 12-weeks

  11. VLDL

    Assessment of changes in VLDL (very low density lipoprotein carrier) over time. Ranges: \< 5-40 mg/dL

    Time frame: 12-weeks

  12. SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)

    Assessment of changes in SAM/SAH (S-adenosylmethionine/S-adenosylhomocysteine) ratio Range: \>4.0

    Time frame: 12-weeks

  13. SAM (S-adenosylmethionine)

    Assessment of changes in SAM (S-adenosylmethionine)

    Time frame: 12-weeks

  14. SAH (S-adenosylhomocysteine)

    Assessment of changes in SAH (S-adenosylhomocysteine) Range: 10-22 nmol/L

    Time frame: 12-weeks

  15. Adenosine

    Assessment of changes in Adenosine Range: 20-80 nmol/L

    Time frame: 12-weeks

06

Results

Posted Nov 12, 2019
Limitations and caveats
No limitations or caveats

Participant flow

Participant flow — Overall Study
MilestoneExperimental GroupControl Group
Started4850
Completed4850
Not completed00

Outcome measures

PrimaryMoCA (Montreal Cognitive Assessment)

Measures changes in cognitive function over time. Score: 30 points (maximum), 0 points (minimum). Score \>25 = normal cognitive function. Score 17-25 = mild cognitive impairment (MCI). Score \<17 = increased likelihood of Alzheimer's Disease or dementia.

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale
MoCA (Montreal Cognitive Assessment)
score on a scaleExperimental GroupControl Group
MoCA (Montreal Cognitive Assessment)28.38 ± 0.2220.22 ± 0.22
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Mean difference (final values): 8.24 · 95% CI 7.79 to 8.7
SecondaryNMR Lipoprofile Particle Size - Small LDL-P

Assessment of changes in Small LDL-P (total small Pattern B)

Time frame:
12 weeks
Reported as:
Geometric least squares mean · nmol/L
NMR Lipoprofile Particle Size - Small LDL-P
nmol/LExperimental GroupControl Group
NMR Lipoprofile Particle Size - Small LDL-P276.24 ± 29.25588.08 ± 61.02
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.35 · 95% CI 0.31 to 0.39
SecondaryNMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45

Lipoprotein insulin resistance (LP-IR) is an aggregate score of the 6 lipoprotein parameters range from 0 to 100, with higher scores indicating greater insulin resistance (IR).

Time frame:
12 weeks
Reported as:
Geometric least squares mean · score on a scale
NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45
score on a scaleExperimental GroupControl Group
NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <4532.13 (28.87 to 35.76)50.66 (45.62 to 56.26)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.46 · 95% CI 0.41 to 0.52
SecondaryFasting Triglycerides

Assessment of changes in fasting triglycerides over time. Ranges: \< 150 mg/dL

Time frame:
12 weeks
Reported as:
Geometric least squares mean · mg/dL
Fasting Triglycerides
mg/dLExperimental GroupControl Group
Fasting Triglycerides87.23 (76.58 to 99.35)131.73 (115.96 to 149.64)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.514 · 95% CI 0.47 to 0.56
SecondaryTriglyceride/HDL Ratio

Assessment of changes in Triglyceride/HDL ratio over time.

Time frame:
12 weeks
Reported as:
Geometric least squares mean · ratio
Triglyceride/HDL Ratio
ratioExperimental GroupControl Group
Triglyceride/HDL Ratio1.67 (1.41 to 1.99)2.69 (2.28 to 3.19)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.44 · 95% CI 0.40 to 0.49
SecondaryFasting Insulin

Assessment of changes in fasting insulin over time. Ranges: \< 2.6-11.1 mU/L

Time frame:
12-weeks
Reported as:
Geometric least squares mean · mU/L
Fasting Insulin
mU/LExperimental GroupControl Group
Fasting Insulin7.32 (6.37 to 8.42)11.25 (9.81 to 12.91)
Statistical analysis
  • Experimental Group vs Control Group · Estimate · p = <0.0001 · Mean difference (final values): 0.44 · 95% CI 0.40 to 0.49
SecondaryFasting Glucose

Assessment of changes in fasting glucose over time. Ranges: \< 74-100 mg/dL

Time frame:
12-weeks
Reported as:
Geometric least squares mean · mg/dL
Fasting Glucose
mg/dLExperimental GroupControl Group
Fasting Glucose85.9 (82.64 to 89.30)109.61 (105.52 to 113.85)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.75 · 95% CI 0.72 to 0.78
SecondaryHOMA-IR

Assessment of changes in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) over time. Ranges: \< 1.0

Time frame:
12-weeks
Reported as:
Geometric least squares mean · units on a scale
HOMA-IR
units on a scaleExperimental GroupControl Group
HOMA-IR1.55 (1.32 to 1.83)3.05 (2.60 to 3.57)
Statistical analysis
  • Experimental Group vs Control Group · Estimate · p = <0.0001 · Mean difference (final values): 0.33 · 95% CI 0.30 to 0.37
SecondaryHgA1c

Assessment of changes in HgA1c (Hemoglobin A1c) over time.

Time frame:
12-weeks
Reported as:
Geometric least squares mean · percentage of glycated hemoglobin
HgA1c
percentage of glycated hemoglobinExperimental GroupControl Group
HgA1c5.19 (5.11 to 5.28)5.82 (5.73 to 5.91)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.87 · 95% CI 0.85 to 0.88
SecondaryWeight

Assessment of changes in weight over time as measured in pounds.

Time frame:
12-weeks
Reported as:
Geometric least squares mean · pounds
Weight
poundsExperimental GroupControl Group
Weight200.23 (189.46 to 211.62)210.60 (199.49 to 222.32)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.87 · 95% CI 0.85 to 0.88
SecondaryBody Fat Mass (BFM)

Assessment of changes in body fat mass over time as measured in pounds.

Time frame:
12-weeks
Reported as:
Geometric least squares mean · pounds
Body Fat Mass (BFM)
poundsExperimental GroupControl Group
Body Fat Mass (BFM)67.95 (62.21 to 74.21)79.35 (72.78 to 86.52)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.75 · 95% CI 0.71 to 0.80
SecondaryVLDL

Assessment of changes in VLDL (very low density lipoprotein carrier) over time. Ranges: \< 5-40 mg/dL

Time frame:
12-weeks
Reported as:
Geometric least squares mean · mg/dL
VLDL
mg/dLExperimental GroupControl Group
VLDL17.45 (15.32 to 19.87)26.35 (23.19 to 29.93)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.51 · 95% CI 0.47 to 0.56
SecondarySAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)

Assessment of changes in SAM/SAH (S-adenosylmethionine/S-adenosylhomocysteine) ratio Range: \>4.0

Time frame:
12-weeks
Reported as:
Geometric least squares mean · ratio
SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)
ratioExperimental GroupControl Group
SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)4.938 (4.538 to 5.372)4.491 (4.119 to 4.896)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 1.130 · 95% CI 1.104 to 1.156
SecondarySAM (S-adenosylmethionine)

Assessment of changes in SAM (S-adenosylmethionine)

Time frame:
12-weeks
Reported as:
Geometric least squares mean · nmol/L
SAM (S-adenosylmethionine)
nmol/LExperimental GroupControl Group
SAM (S-adenosylmethionine)89.784 (84.767 to 95.099)88.177 (83.131 to 93.529)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 1.037 · 95% CI 1.025 to 1.049
SecondarySAH (S-adenosylhomocysteine)

Assessment of changes in SAH (S-adenosylhomocysteine) Range: 10-22 nmol/L

Time frame:
12-weeks
Reported as:
Geometric least squares mean · nmol/L
SAH (S-adenosylhomocysteine)
nmol/LExperimental GroupControl Group
SAH (S-adenosylhomocysteine)18.257 (17.685 to 18.847)19.566 (18.938 to 20.214)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 0.93 · 95% CI 0.91 to 0.94
SecondaryAdenosine

Assessment of changes in Adenosine Range: 20-80 nmol/L

Time frame:
12-weeks
Reported as:
Geometric least squares mean · nmol/L
Adenosine
nmol/LExperimental GroupControl Group
Adenosine23.363 (22.413 to 24.352)21.475 (20.581 to 22.407)
Statistical analysis
  • Experimental Group vs Control Group · Regression, Linear · p = <0.0001 · Estimate: 1.122 · 95% CI 1.096 to 1.149

Adverse events

Collected over 12-weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Group0/48 (0%)0/48 (0%)0/48 (0%)
Control Group0/50 (0%)0/50 (0%)0/50 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental GroupControl GroupTotal
<=18 years000
Between 18 and 65 years414485
>=65 years7613
Sex: Female, Male
Sex: Female, Male(Participants)Experimental GroupControl GroupTotal
Female252550
Male232548
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Experimental GroupControl GroupTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Experimental GroupControl GroupTotal
United States485098
MoCA (Montreal Cognitive Assessment)
MoCA (Montreal Cognitive Assessment)(units on a scale)Experimental GroupControl GroupTotal
Least squares mean28.38 (27.94 to 28.81)20.22 (19.79 to 20.64)24.30 (23.50 to 25.1)
07

Study locations

1 site
  • Bristlecone Health, Inc.
    Maple Grove, Minnesota 55311, United States
08

References and documents

Study documents

  • Study protocol · Sep 15, 2017
  • Statistical analysis plan · Jan 15, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03319173
Lead sponsor
Bristlecone Health, Inc.
Collaborators
University of Minnesota
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Oct 15, 2017
Primary completion
Sep 30, 2018
Completion
Sep 30, 2018
Results posted
Nov 12, 2019
Last update
Nov 12, 2019

Study contacts

Kelly J Gibas, Doctorate
principal investigator · Bristlecone Health, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion